A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Astellas Pharma US, Inc.

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed unresectable stage III or IV malignant melanoma

• Life expectancy >12 weeks

Exclusion Criteria:

• History of other malignancy in the last 5 years

• Major surgery within the past 21 days